Company intelligence / Profile preview

Hilong

Ownership: Private
Development stage: Commercial

Overview

HiLung has developed a proprietary human lung organoid platform that enables mass production of human respiratory epithelial cells replicating both normal and diseased states. This technology accelerates preclinical drug discovery for respiratory diseases by providing highly physiologically relevant models. The company is also working toward enabling future cell and tissue therapies for the lung[1].

Therapeutic areas: Pulmonology
Modalities: Cell therapyTissue therapyOrganoid-based platform (for drug discovery and preclinical testing)Induced pluripotent stem cell derived therapy (iPSC-derived cells)
Industry: Non-Drug Biotech

Partnerships

Not explicitly listed, but presentations at events hosted by Johnson & Johnson and BARDA suggest industry engagement[1]

Beyond the preview

Go deeper on Hilong.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hilong.

Explore the full profile